Table 1.
Cohort demographics and concomitant medications
| All races combined (N = 1,312) | White subjects only (N = 845) | Black subjects only (N = 222) | |
|---|---|---|---|
| Intensive glycemia arm |
56.33 |
59.41 |
53.15 |
| Standard glycemia arm |
43.67 |
40.59 |
46.85 |
| Intensive blood pressure arm |
23.86 |
23.67 |
34.23 |
| Standard blood pressure arm |
23.78 |
21.89 |
33.33 |
| Fibrate lipid treatment arm |
25.99 |
25.68 |
14.41 |
| Placebo lipid treatment arm |
26.37 |
28.76 |
18.01 |
| Female |
39.48 |
36.33 |
52.70 |
| Age (mean [95% CI]) |
62.72 [62.36, 63.10] |
63.14 [62.70, 63.58] |
62.25 [61.37, 63.12] |
| BMI (mean [95% CI]) |
32.43 [32.13, 32.73] |
33.18 [32.82, 33.54] |
32.67 [31.94, 33.39] |
| Years with T2D (mean [95% CI]) |
10.10 [9.67, 10.51] |
9.73 [9.23, 10.24] |
10.82 [9.76, 11.87] |
| History of cardiovascular disease |
33.54 |
35.27 |
29.28 |
| Concomitant medications* | |||
| Angiotensin type 2 antagonists |
16.39 |
15.98 |
16.67 |
| ACE inhibitors |
46.19 |
46.98 |
52.25 |
| α-Glucosidase inhibitors |
0.53 |
0.47 |
0.45 |
| Cholesterol absorption inhibitors |
2.13 |
2.49 |
1.80 |
| Statin |
49.70 |
51.83 |
30.18 |
| Lisinopril |
16.46 |
16.45 |
25.23 |
| Loop diuretics |
8.23 |
8.99 |
10.36 |
| Meglitinides |
2.97 |
2.37 |
3.15 |
| Nitrates |
5.72 |
6.51 |
3.60 |
| Other diabetes treatments |
2.67 |
2.84 |
4.05 |
| Sulfonylureas |
52.44 |
51.83 |
45.05 |
| Thiazolidinediones |
31.63 |
33.02 |
29.28 |
| Insulin | 38.11 | 38.11 | 45.95 |
Data are %, unless stated otherwise.
*Tabulated percentages represent the percentage of subjects with at least one record of taking the medication or a medication in the drug class during the metformin treatment window. This is not an exhaustive list of medications recorded in ACCORD, but rather a representative list of the commonly used medications in ACCORD.